| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000025798 |
| Receipt No. | R000029669 |
| Scientific Title | Randomized, double-blind, crossover, confirmation test of cold sensitivity and blood flow improving function by ingesting test food. |
| Date of disclosure of the study information | 2017/01/23 |
| Last modified on | 2020/10/05 (Ver. 5) |
| Basic information | ||
| Public title | Randomized, double-blind, crossover, confirmation test of cold sensitivity and blood flow improving function by ingesting test food. | |
| Acronym | Randomized, double-blind, crossover, confirmation test of cold sensitivity and blood flow improving function by ingesting test food. | |
| Scientific Title | Randomized, double-blind, crossover, confirmation test of cold sensitivity and blood flow improving function by ingesting test food. | |
| Scientific Title:Acronym | Randomized, double-blind, crossover, confirmation test of cold sensitivity and blood flow improving function by ingesting test food. | |
| Region |
|
|
| Condition | ||
| Condition | Females in good health | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To confirm improving function of cold sensitivity and blood flow of test food. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Body surface temperature and blood flow after 2 weeks ingestion of test food. |
| Key secondary outcomes | Blood NOx concentration on 60min after test food ingestion.
Questionnaire after 2 weeks ingestion of test food. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingesting test food, 2 tablets after completion of morning meal for 2 weeks. After 2 weeks of washout period, ingesting placebo food, 2 tablets in a day for 2 weeks. | |
| Interventions/Control_2 | Ingesting test food, 2 tablets after completion of morning meal for 2 weeks. After 2 weeks of washout period, ingesting test food, 2 tablets in a day for 2 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1) Females aged over 20 years old when obtaining informed consent.
2) Subjects who have subjective symptoms of cold sensitivity. 3) Subjects who show understanding of the study procedures and agreement with participating the study by written informed consent prior to the study. |
|||
| Key exclusion criteria | 1) Subjects who were diagnosed as chilliness by medical doctor.
2) Subjects who ingest medicines and/or supplement regularly for improving fatigue, blood flow, cold sensitivity or stress. 3) Pregnant or possibly pregnant women, or lactating women. 4) Subjects who have previous and/or current medical history of serious disease in heart, liver, kidney and/or digestive trucks. 5) Subjects who excessive alcohol intake. 6) Subjects who have extremely irregular life rhythms, and subjects who have midnight work or irregular shift work. 7) Subjects who have previous medical history of drug and/or food allergy. 8) Subjects who are participating the other clinical tests of medicines or foods. Subjects who participated other clinical tests of medicines or foods within 4-weeks prior to the current study. 9) Subjects who donated over 200mL blood and/or blood components within a month to the current study. 10) Subjects who donated over 400mL blood within the last four months to the current study. 11) Subjects who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 12) Subjects who have been determined ineligible by principal investigator or sub-investigator. |
|||
| Target sample size | 25 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan | ||||||
| TEL | 03-5297-3112 | ||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Plan Sales Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan | ||||||
| TEL | 03-5297-3112 | ||||||
| Homepage URL | |||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Funding Source | |
| Organization | TAIHO PHARMACEUTICAL CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029669 |